Want to see AU:RAD full AI Analyst Report?
RAD Stock Chart & Stats
AU$0.01
>-AU$0.01(-26.32%)
At close: 4:00 PM EDT
AU$0.01
>-AU$0.01(-26.32%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.04
Previous CloseN/A
Volume31.52M
Average Volume (3M)4.84M
Market Cap
AU$39.04M
Enterprise ValueAU$52.25
Total Cash (Recent Filing)AU$4.14M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.96
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding4,337,549,300
10 Day Avg. Volume4,365,338
30 Day Avg. Volume4,842,346
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)2.73
Price to Sales (P/S)24.33
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market ExposureThe launch of American Depository Shares, with plans for a secondary listing on Nasdaq, positions Radiopharm for broader market exposure.
Partnership OpportunitiesRadiopharm's portfolio of imaging and therapeutic radiopharmaceutical agents provides the company with opportunities for medium- to long-term growth and potential non-dilutive capital via partnerships.
Therapeutic PipelineRadiopharm Theranostics has focused its therapeutic pipeline on biologically validated targets that have seen limited or no use in radiopharmaceuticals, which is designed to de-risk development and limit competition.
Bears Say
Capital RaiseThe AUD 70M capital raise resulted in higher dilution than previously estimated due to associated lower prices.
Radiopharm Theranostics Limited News
RAD FAQ
What was Radiopharm Theranostics Limited’s price range in the past 12 months?
Radiopharm Theranostics Limited lowest share price was <AU$0.01 and its highest was AU$0.04 in the past 12 months.
What is Radiopharm Theranostics Limited’s market cap?
Radiopharm Theranostics Limited’s market cap is AU$39.04M.
When is Radiopharm Theranostics Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Radiopharm Theranostics Limited’s earnings last quarter?
Currently, no data Available
Is Radiopharm Theranostics Limited overvalued?
According to Wall Street analysts Radiopharm Theranostics Limited’s price is currently Overvalued.
Does Radiopharm Theranostics Limited pay dividends?
Radiopharm Theranostics Limited does not currently pay dividends.
What is Radiopharm Theranostics Limited’s EPS estimate?
Radiopharm Theranostics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Radiopharm Theranostics Limited have?
Radiopharm Theranostics Limited has 4,337,549,300 shares outstanding.
What happened to Radiopharm Theranostics Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Radiopharm Theranostics Limited?
Currently, no hedge funds are holding shares in AU:RAD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Radiopharm Theranostics Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:RAD Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.58%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-30.47%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Radiopharm Theranostics Limited
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.